202 related articles for article (PubMed ID: 11008016)
1. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay.
Rasmussen T; Poulsen TS; Honoré L; Johnsen HE
Exp Hematol; 2000 Sep; 28(9):1039-45. PubMed ID: 11008016
[TBL] [Abstract][Full Text] [Related]
2. Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients.
Sata H; Shibayama H; Maeda I; Habuchi Y; Nakatani E; Fukushima K; Fujita J; Ezoe S; Tadokoro S; Maeda T; Mizuki M; Kosugi S; Nakagawa M; Ueda S; Iida M; Tokumine Y; Azenishi Y; Mitsui H; Oritani K; Kanakura Y
Exp Hematol; 2015 May; 43(5):374-381.e2. PubMed ID: 25591497
[TBL] [Abstract][Full Text] [Related]
3. Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma.
Ladetto M; Donovan JW; Harig S; Trojan A; Poor C; Schlossnan R; Anderson KC; Gribben JG
Biol Blood Marrow Transplant; 2000; 6(3):241-53. PubMed ID: 10871149
[TBL] [Abstract][Full Text] [Related]
4. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S
Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584
[TBL] [Abstract][Full Text] [Related]
5. Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma.
Martinez-Lopez J; Martinez-Sanchez P; Garcia-Sanz R; Sarasquete ME; Ayala R; Gonzalez M; Bautista JM; Gonzalez D; San Miguel J; Garcia-Effron G; Lahuerta JJ
J Mol Diagn; 2006 Jul; 8(3):364-70. PubMed ID: 16825510
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF
Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573
[TBL] [Abstract][Full Text] [Related]
7. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes.
Bai Y; Wong KY; Fung TK; Chim CS
J Hematol Oncol; 2016 Oct; 9(1):107. PubMed ID: 27724958
[TBL] [Abstract][Full Text] [Related]
8. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
Kara IO; Duman BB; Afsar CU
J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
[TBL] [Abstract][Full Text] [Related]
9. Improved quantitation of minimal residual disease in multiple myeloma using real-time polymerase chain reaction and plasmid-DNA complementarity determining region III standards.
Gerard CJ; Olsson K; Ramanathan R; Reading C; Hanania EG
Cancer Res; 1998 Sep; 58(17):3957-64. PubMed ID: 9731509
[TBL] [Abstract][Full Text] [Related]
10. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
12. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
[TBL] [Abstract][Full Text] [Related]
13. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
[TBL] [Abstract][Full Text] [Related]
14. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.
Puig N; Sarasquete ME; Balanzategui A; Martínez J; Paiva B; García H; Fumero S; Jiménez C; Alcoceba M; Chillón MC; Sebastián E; Marín L; Montalbán MA; Mateos MV; Oriol A; Palomera L; de la Rubia J; Vidriales MB; Bladé J; Lahuerta JJ; González M; Miguel JF; García-Sanz R
Leukemia; 2014 Feb; 28(2):391-7. PubMed ID: 23860448
[TBL] [Abstract][Full Text] [Related]
15. The use of IgH fingerprinting and ASO-dependent PCR for the investigation of residual disease (MRD) in ALL.
Chim JC; Coyle LA; Yaxley JC; Cole-Sinclair MF; Cannell PK; Hoffbrand VA; Foroni L
Br J Haematol; 1996 Jan; 92(1):104-15. PubMed ID: 8562380
[TBL] [Abstract][Full Text] [Related]
16. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.
Compagno M; Mantoan B; Astolfi M; Boccadoro M; Ladetto M
Methods Mol Med; 2005; 113():145-63. PubMed ID: 15968100
[TBL] [Abstract][Full Text] [Related]
17. Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation.
Lipinski E; Cremer FW; Ho AD; Goldschmidt H; Moos M
Bone Marrow Transplant; 2001 Nov; 28(10):957-62. PubMed ID: 11753551
[TBL] [Abstract][Full Text] [Related]
18. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
[TBL] [Abstract][Full Text] [Related]
19. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients.
Billadeau D; Quam L; Thomas W; Kay N; Greipp P; Kyle R; Oken MM; Van Ness B
Blood; 1992 Oct; 80(7):1818-24. PubMed ID: 1391945
[TBL] [Abstract][Full Text] [Related]
20. Quantitative assessment of minimal residual disease in childhood lymphoid malignancies using an allele-specific oligonucleotide real-time quantitative polymerase chain reaction.
Tarusawa M; Yashima A; Endo M; Maesawa C
Int J Hematol; 2002 Feb; 75(2):166-73. PubMed ID: 11939263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
